Aldevron News

Aldevron Announces Availability of GMP SpCas9

Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services, announces the availability of GMP-grade SpCas9 nuclease for use in clinical development programs.  Aldevron’s GMP SpCas9 is designed to accelerate gene editing clinical trials and commercial applications by providing an immediate enzyme supply; thereby eliminating months typically associated with contract GMP production and testing.

“The release of Aldevron’s first GMP Cas9 is another milestone in the company’s commitment to our partners in gene editing,” said Michael Chambers, Aldevron Chief Executive Officer.  “Our clients are able to purchase GMP and GMP Source™ SpCas9 as an off-the-shelf product, eliminating the production time and significantly reducing the cost compared to custom manufacturing.  Aldevron’s Cas9 product line assures clients a consistent supply of the nuclease through all stages of their development programs.” Chambers added that more GMP gene editing enzymes will be released in the near future.

Aldevron’s SpCas9 has been shown by researchers at the University of Wisconsin-Madison and the University of Minnesota to be highly efficient and consistent from lot to lot.  The high concentration and formulation of the nuclease allow for considerable flexibility in experimental design and expand the options for gene editing applications.  Licensed clients who are interested in a sample of Aldevron’s research grade SpCas9 (same construct as GMP SpCas9) can visit the Cas9 sample request page.

About Aldevron

Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmid DNA, RNA and gene editing enzymes for research, clinical, and commercial applications. Aldevron's clients are developing revolutionary treatments in many fields including oncology, neuroscience, infectious disease and rare diseases. Company headquarters are in Fargo, N.D., with additional facilities in Madison, Wis., and Freiburg, Germany.

Topics: Gene Editing, CRISPR, Cas9

Comments